熱門資訊> 正文
指南针抑郁症资产数据公布后，迷幻药股下跌
2025-06-24 03:24
- Most companies operating in the psychedelic medicine space are down significantly after Compass Pathways (NASDAQ:CMPS) on Monday posted late-stage data on its psilocybin-based treatment for treatment-resistant depression that left many on the Street disappointed.
- atai Life Sciences (NASDAQ:ATAI), which has an oral film version of N, N-Dimethyltryptamine (DMT) in phase 2, also for treatment-resistant depression, is off ~15%.
- MindMed (NASDAQ:MNMD), which has a form of LSD in phase 3 for major depressive disorder, is down ~6%.
- Cybin (NYSE:CYBN), which has an oral, deuterated psilocin asset in phase 2 as an adjunct treatment for depression, is down ~5%.
- GH Research (NASDAQ:GHRS), which has an inhalation mebufotenin candidate in phase 2 for treatment-resistant depression, is off ~5%.
- Other names in the space that are struggling today include Clearmind Medicine (NASDAQ:CMND), Enveric Biosciences (NASDAQ:ENVB), and Bright Minds Biosciences (NASDAQ:DRUG).
More on Mind Medicine, atai Life Sciences,
- Mind Medicine (MindMed) Inc. (MNMD) Q1 2025 Earnings Call Transcript
- Mind Medicine (MindMed) Inc. 2025 Q1 - Results - Earnings Call Presentation
- Mind Medicine: Strong Data, But Psychedelic Stigma Still Clouds Investor Confidence
- atai Life Sciences and Beckley Psytech merging
- Psychedelic stocks rise as FDA chief’s comments seen favorable to industry
推薦文章
一周財經日曆丨降息信號將定？下周全球央行年會成關鍵；小米、泡泡瑪特、快手領銜港股財報潮
港股周報丨見證歷史！南向資金單日瘋狂買入港股359億港元；騰訊績后股價一度升破600港元
特朗普政府據悉考慮動用芯片法案資金來入股英特爾
美股機會日報丨「恐怖數據」符合預期，交易員下調美聯儲降息預期；巴菲特Q2新建倉股飆升，聯合健康盤前漲超10%
銀諾醫藥-B上市首日暴漲285%，一手賺超1萬港元
投資大佬Tepper減持阿里巴巴、京東等 買入股價暴跌的聯合健康
伯克希爾減持蘋果股份 增持聯合健康集團
8月15日外盤頭條：特朗普政府洽購英特爾股份 貝森特否認推動降息 蘋果重新設計Apple Watch血氧功能
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
